vorikonazol accordpharma 200 mg prašak za otopinu za infuziju
accord healthcare polska sp. z o.o., ul. tasmowa 7, mazowieckie, varšava, poljska - voriconazolum - prašak za otopinu za infuziju - 200 mg - urbroj: jedna bočica sadrži 200 mg vorikonazola
daptomicin accordpharma 500 mg prašak za otopinu za injekciju/infuziju
accord healthcare polska sp. z o.o., ul. tasmowa 7, mazowieckie, varšava, poljska - daptomicin - prašak za otopinu za injekciju / infuziju - 500 mg - urbroj: jedna bočica s praškom sadrži 500 mg daptomicina jedan ml otopine nakon rekonstitucije s 10 ml otopine natrijevog klorida 9 mg/ml (0,9%) sadrži 50 mg daptomicina
iasibon
pharmathen s.a. - ibandroninska kiselina - hypercalcemia; fractures, bone; neoplasm metastasis; breast neoplasms - lijekovi za liječenje bolesti kostiju - concentrate for solution for infusion prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases. liječenje tumor-induced гиперкальциемии sa ili bez metastaza. film-coated tablets prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases.
ledaga
helsinn birex pharmaceuticals ltd. - chlormethine - mycosis fungoides - antineoplastična sredstva - ledaga je indicirana za topičko liječenje limfoma t-stanica (tipa mf-tipa ctcl) tipa mikoza fungoida u bolesnika odraslih.
lacydyna 6 mg filmom obložene tablete
double-e pharma ltd., 17 corrig road, sandyford, irska - lacidipin - filmom obložena tableta - 6 mg - urbroj: svaka filmom obložena tableta sadržava 6 mg lacidipina
lacydyna 4 mg filmom obložene tablete
double-e pharma ltd., 17 corrig road, sandyford, irska - lacidipin - filmom obložena tableta - 4 mg - urbroj: svaka filmom obložena tableta sadržava 4 mg lacidipina
rivomox 400 mg filmom obložene tablete
double-e pharma ltd., 7th floor, hume house, ballsbridge, dublin, irska - moksifloksacinklorid - filmom obložena tableta - 400 mg - urbroj: svaka filmom obložena tableta sadrži 400 mg moksifloksacina (u obliku klorida)
visipaque 270 mg i/ml, otopina za injekciju
ge healthcare as, nycoveien 1, oslo, norveška - jodiksanol - otopina za injekciju - 270 mg/ml - urbroj: 1 ml otopine sadrži 550 mg jodiksanola što odgovara 270 mg joda
visipaque 320 mg i/ml, otopina za injekciju
ge healthcare as, nycoveien 1, oslo, norveška - jodiksanol - otopina za injekciju - 320 mg/ml - urbroj: 1 ml otopine sadrži 652 mg jodiksanola što odgovara 320 mg joda
rivaroxaban viatris (previously rivaroxaban mylan)
mylan ireland limited - rivaroksaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - antitrombotska sredstva - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers. rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery. treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.